Compare SLN & HBCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLN | HBCP |
|---|---|---|
| Founded | 1994 | 1908 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 678.0M | 546.5M |
| IPO Year | 2010 | 2008 |
| Metric | SLN | HBCP |
|---|---|---|
| Price | $11.51 | $67.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $42.60 | ★ $65.50 |
| AVG Volume (30 Days) | ★ 647.9K | 50.3K |
| Earning Date | 05-07-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 1.98% |
| EPS Growth | N/A | ★ 29.01 |
| EPS | N/A | ★ 2.93 |
| Revenue | ★ $559,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.97 |
| P/E Ratio | ★ N/A | $23.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.19 | $50.54 |
| 52 Week High | $17.58 | $74.50 |
| Indicator | SLN | HBCP |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | N/A |
| Support Level | $4.70 | N/A |
| Resistance Level | $15.28 | N/A |
| Average True Range (ATR) | 0.58 | 0.00 |
| MACD | -0.23 | 0.00 |
| Stochastic Oscillator | 10.46 | 0.00 |
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities.It is holding company for Home Bank, N.A. The principal sources of funds are customer deposits, repayments of loans, repayments of investments, and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.